Copyright Reports & Markets. All rights reserved.

Global Antifibrotic Drug Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Antifibrotic Drug Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Nintedanib
    • 1.3.3 Pirfenidone
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Antifibrotic Drug Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital and Clinic
    • 1.4.3 Retail Pharmacies
    • 1.4.4 Other
  • 1.5 Global Antifibrotic Drug Market Size & Forecast
    • 1.5.1 Global Antifibrotic Drug Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Antifibrotic Drug Sales Quantity (2021-2032)
    • 1.5.3 Global Antifibrotic Drug Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Boehringer Ingelheim
    • 2.1.1 Boehringer Ingelheim Details
    • 2.1.2 Boehringer Ingelheim Major Business
    • 2.1.3 Boehringer Ingelheim Antifibrotic Drug Product and Services
    • 2.1.4 Boehringer Ingelheim Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Boehringer Ingelheim Recent Developments/Updates
  • 2.2 Roche
    • 2.2.1 Roche Details
    • 2.2.2 Roche Major Business
    • 2.2.3 Roche Antifibrotic Drug Product and Services
    • 2.2.4 Roche Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Roche Recent Developments/Updates
  • 2.3 Accord Healthcare
    • 2.3.1 Accord Healthcare Details
    • 2.3.2 Accord Healthcare Major Business
    • 2.3.3 Accord Healthcare Antifibrotic Drug Product and Services
    • 2.3.4 Accord Healthcare Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Accord Healthcare Recent Developments/Updates
  • 2.4 Amneal Pharmaceuticals
    • 2.4.1 Amneal Pharmaceuticals Details
    • 2.4.2 Amneal Pharmaceuticals Major Business
    • 2.4.3 Amneal Pharmaceuticals Antifibrotic Drug Product and Services
    • 2.4.4 Amneal Pharmaceuticals Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Amneal Pharmaceuticals Recent Developments/Updates
  • 2.5 Sandoz
    • 2.5.1 Sandoz Details
    • 2.5.2 Sandoz Major Business
    • 2.5.3 Sandoz Antifibrotic Drug Product and Services
    • 2.5.4 Sandoz Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Sandoz Recent Developments/Updates
  • 2.6 Teva
    • 2.6.1 Teva Details
    • 2.6.2 Teva Major Business
    • 2.6.3 Teva Antifibrotic Drug Product and Services
    • 2.6.4 Teva Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Teva Recent Developments/Updates
  • 2.7 ScieGen Pharmaceuticals
    • 2.7.1 ScieGen Pharmaceuticals Details
    • 2.7.2 ScieGen Pharmaceuticals Major Business
    • 2.7.3 ScieGen Pharmaceuticals Antifibrotic Drug Product and Services
    • 2.7.4 ScieGen Pharmaceuticals Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 ScieGen Pharmaceuticals Recent Developments/Updates
  • 2.8 Apotex
    • 2.8.1 Apotex Details
    • 2.8.2 Apotex Major Business
    • 2.8.3 Apotex Antifibrotic Drug Product and Services
    • 2.8.4 Apotex Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Apotex Recent Developments/Updates
  • 2.9 Gyre Pharmaceuticals
    • 2.9.1 Gyre Pharmaceuticals Details
    • 2.9.2 Gyre Pharmaceuticals Major Business
    • 2.9.3 Gyre Pharmaceuticals Antifibrotic Drug Product and Services
    • 2.9.4 Gyre Pharmaceuticals Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Gyre Pharmaceuticals Recent Developments/Updates
  • 2.10 Kawin
    • 2.10.1 Kawin Details
    • 2.10.2 Kawin Major Business
    • 2.10.3 Kawin Antifibrotic Drug Product and Services
    • 2.10.4 Kawin Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Kawin Recent Developments/Updates
  • 2.11 Beacon Pharma
    • 2.11.1 Beacon Pharma Details
    • 2.11.2 Beacon Pharma Major Business
    • 2.11.3 Beacon Pharma Antifibrotic Drug Product and Services
    • 2.11.4 Beacon Pharma Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Beacon Pharma Recent Developments/Updates
  • 2.12 Eskayef Pharmaceuticals
    • 2.12.1 Eskayef Pharmaceuticals Details
    • 2.12.2 Eskayef Pharmaceuticals Major Business
    • 2.12.3 Eskayef Pharmaceuticals Antifibrotic Drug Product and Services
    • 2.12.4 Eskayef Pharmaceuticals Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Eskayef Pharmaceuticals Recent Developments/Updates
  • 2.13 CSPC Pharmaceutical Group
    • 2.13.1 CSPC Pharmaceutical Group Details
    • 2.13.2 CSPC Pharmaceutical Group Major Business
    • 2.13.3 CSPC Pharmaceutical Group Antifibrotic Drug Product and Services
    • 2.13.4 CSPC Pharmaceutical Group Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 CSPC Pharmaceutical Group Recent Developments/Updates
  • 2.14 Qilu Pharmaceutical
    • 2.14.1 Qilu Pharmaceutical Details
    • 2.14.2 Qilu Pharmaceutical Major Business
    • 2.14.3 Qilu Pharmaceutical Antifibrotic Drug Product and Services
    • 2.14.4 Qilu Pharmaceutical Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Qilu Pharmaceutical Recent Developments/Updates
  • 2.15 Kelun Pharmaceutical
    • 2.15.1 Kelun Pharmaceutical Details
    • 2.15.2 Kelun Pharmaceutical Major Business
    • 2.15.3 Kelun Pharmaceutical Antifibrotic Drug Product and Services
    • 2.15.4 Kelun Pharmaceutical Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Kelun Pharmaceutical Recent Developments/Updates
  • 2.16 PuraCap
    • 2.16.1 PuraCap Details
    • 2.16.2 PuraCap Major Business
    • 2.16.3 PuraCap Antifibrotic Drug Product and Services
    • 2.16.4 PuraCap Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 PuraCap Recent Developments/Updates

3 Competitive Environment: Antifibrotic Drug by Manufacturer

  • 3.1 Global Antifibrotic Drug Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Antifibrotic Drug Revenue by Manufacturer (2021-2026)
  • 3.3 Global Antifibrotic Drug Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Antifibrotic Drug by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Antifibrotic Drug Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Antifibrotic Drug Manufacturer Market Share in 2025
  • 3.5 Antifibrotic Drug Market: Overall Company Footprint Analysis
    • 3.5.1 Antifibrotic Drug Market: Region Footprint
    • 3.5.2 Antifibrotic Drug Market: Company Product Type Footprint
    • 3.5.3 Antifibrotic Drug Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Antifibrotic Drug Market Size by Region
    • 4.1.1 Global Antifibrotic Drug Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Antifibrotic Drug Consumption Value by Region (2021-2032)
    • 4.1.3 Global Antifibrotic Drug Average Price by Region (2021-2032)
  • 4.2 North America Antifibrotic Drug Consumption Value (2021-2032)
  • 4.3 Europe Antifibrotic Drug Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Antifibrotic Drug Consumption Value (2021-2032)
  • 4.5 South America Antifibrotic Drug Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Antifibrotic Drug Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Antifibrotic Drug Sales Quantity by Type (2021-2032)
  • 5.2 Global Antifibrotic Drug Consumption Value by Type (2021-2032)
  • 5.3 Global Antifibrotic Drug Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Antifibrotic Drug Sales Quantity by Application (2021-2032)
  • 6.2 Global Antifibrotic Drug Consumption Value by Application (2021-2032)
  • 6.3 Global Antifibrotic Drug Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Antifibrotic Drug Sales Quantity by Type (2021-2032)
  • 7.2 North America Antifibrotic Drug Sales Quantity by Application (2021-2032)
  • 7.3 North America Antifibrotic Drug Market Size by Country
    • 7.3.1 North America Antifibrotic Drug Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Antifibrotic Drug Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Antifibrotic Drug Sales Quantity by Type (2021-2032)
  • 8.2 Europe Antifibrotic Drug Sales Quantity by Application (2021-2032)
  • 8.3 Europe Antifibrotic Drug Market Size by Country
    • 8.3.1 Europe Antifibrotic Drug Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Antifibrotic Drug Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Antifibrotic Drug Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Antifibrotic Drug Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Antifibrotic Drug Market Size by Region
    • 9.3.1 Asia-Pacific Antifibrotic Drug Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Antifibrotic Drug Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Antifibrotic Drug Sales Quantity by Type (2021-2032)
  • 10.2 South America Antifibrotic Drug Sales Quantity by Application (2021-2032)
  • 10.3 South America Antifibrotic Drug Market Size by Country
    • 10.3.1 South America Antifibrotic Drug Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Antifibrotic Drug Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Antifibrotic Drug Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Antifibrotic Drug Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Antifibrotic Drug Market Size by Country
    • 11.3.1 Middle East & Africa Antifibrotic Drug Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Antifibrotic Drug Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Antifibrotic Drug Market Drivers
  • 12.2 Antifibrotic Drug Market Restraints
  • 12.3 Antifibrotic Drug Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Antifibrotic Drug and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Antifibrotic Drug
  • 13.3 Antifibrotic Drug Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Antifibrotic Drug Typical Distributors
  • 14.3 Antifibrotic Drug Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Antifibrotic Drug market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Antifibrotic drugs are medications specifically designed to inhibit or slow down the process of fibrosis.The two main antifibrotic agents used for IPF are pirfenidone and nintedanib.Pirfenidone works by inhibiting processes involved in fibrosis,including reducing the production of pro-inflammatory cytokines and inhibiting fibroblast proliferation and collagen synthesis.Nintedanib,on the other hand,targets multiple tyrosine kinases that are implicated in pathways leading to fibrosis,thereby interfering with the progression of lung scarring.
    This report is a detailed and comprehensive analysis for global Antifibrotic Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Antifibrotic Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Antifibrotic Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Antifibrotic Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Antifibrotic Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Antifibrotic Drug
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Antifibrotic Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boehringer Ingelheim, Roche, Accord Healthcare, Amneal Pharmaceuticals, Sandoz, Teva, ScieGen Pharmaceuticals, Apotex, Gyre Pharmaceuticals, Kawin, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Antifibrotic Drug market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Nintedanib
    Pirfenidone
    Market segment by Application
    Hospital and Clinic
    Retail Pharmacies
    Other
    Major players covered
    Boehringer Ingelheim
    Roche
    Accord Healthcare
    Amneal Pharmaceuticals
    Sandoz
    Teva
    ScieGen Pharmaceuticals
    Apotex
    Gyre Pharmaceuticals
    Kawin
    Beacon Pharma
    Eskayef Pharmaceuticals
    CSPC Pharmaceutical Group
    Qilu Pharmaceutical
    Kelun Pharmaceutical
    PuraCap
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Antifibrotic Drug product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Antifibrotic Drug, with price, sales quantity, revenue, and global market share of Antifibrotic Drug from 2021 to 2026.
    Chapter 3, the Antifibrotic Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Antifibrotic Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Antifibrotic Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Antifibrotic Drug.
    Chapter 14 and 15, to describe Antifibrotic Drug sales channel, distributors, customers, research findings and conclusion.

    Buy now